IndraLab
Statements
reach
"By modulating Foxp3 and Tip60, a prior research found that genetic or pharmacologic targeting of USP7 may block the inhibitory activities of Foxp3 Tregs and preserve normal T cell responses, reducing tumor development and enhancing the efficiency of anti-PD-1 monoclonal antibodies.98 Therefore, the further development and clinical testing of USP7 inhibitors combined with PD-L1/PD-1 checkpoint inhibitors may provide a new valuable approach for cancer immunotherapy."